Intracellular Delivery III

Market Entry Barriers of Nanomedicines

Nonfiction, Science & Nature, Technology, Nanotechnology, Health & Well Being, Medical
Cover of the book Intracellular Delivery III by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319435251
Publisher: Springer International Publishing Publication: October 31, 2016
Imprint: Springer Language: English
Author:
ISBN: 9783319435251
Publisher: Springer International Publishing
Publication: October 31, 2016
Imprint: Springer
Language: English

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new “drugs” will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently “nanomaterials” have been said to “show promise” but none of these promises have so far been “reduced” to human clinical practice. 

The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. 

Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug–carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile. 

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new “drugs” will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently “nanomaterials” have been said to “show promise” but none of these promises have so far been “reduced” to human clinical practice. 

The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. 

Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug–carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile. 

More books from Springer International Publishing

Cover of the book Targeting the DNA Damage Response for Anti-Cancer Therapy by
Cover of the book Root Biology by
Cover of the book Citizenship in Transnational Perspective by
Cover of the book Climate Change, Ocean Acidification and Sponges by
Cover of the book Algorithms and Architectures for Parallel Processing by
Cover of the book Fundamentals of Piano Pedagogy by
Cover of the book Algorithms and Architectures for Parallel Processing by
Cover of the book Diagnostic Techniques in Industrial Engineering by
Cover of the book Continuum Thermodynamics by
Cover of the book Building Resilience of Human-Natural Systems of Pastoralism in the Developing World by
Cover of the book Contemporary Issues in Geoenvironmental Engineering by
Cover of the book Dynamics of Mechanical Systems with Non-Ideal Excitation by
Cover of the book Early Geological Maps of Europe by
Cover of the book Liquidity Risk, Efficiency and New Bank Business Models by
Cover of the book Enterprise and Organizational Modeling and Simulation by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy